ClinicalTrials.gg
CompletedNCT03604692Updated Sep 15, 2025Results posted

A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

A Phase 1/2 interventional study of axatilimab in Chronic Graft-versus-host-disease, sponsored by Syndax Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Syndax Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome — 5 open to participants now, 9 under way, 3 of them phase 3. axatilimab · Bronchiolitis Obliterans Syndrome.

Enrollment
7th of 10
41 · median 50
Started
2018
the only one that year
Phase 1/2
2 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
2 of 10
Syndax Pharmaceuticals

Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1/2, and was the 1st registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

5 of the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About axatilimab

axatilimab: first FDA approval 2024 (NIKTIMVO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD).

Read the detailed description

This is a dose escalation and dose expansion study in participants with active cGVHD who have received at least 2 lines of prior therapy.

03

Conditions studied

  • Chronic Graft-versus-host-disease

Keywords

  • cGVHD
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participant must be 6 years of age or older, at the time of signing the .
  2. Participants who are hematopoietic stem cell transplant (HSCT) recipients with cGVHD requiring systemic immune suppression.
  3. Participants with active cGVHD who have received at least 2 . Participants 18 or older with active cGVHD who have erythematous rash involving >25% body surface area or a NIH mouth score of >4 must have received prior ibrutinib therapy.

    a. Active cGVHD is defined as the presence of signs and symptoms of cGVHD per 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.

  4. Participants may have persistent active acute and cGVHD manifestations (overlap syndrome), as defined by 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
  5. Performance Scale of ≥60 with a of at least 3 months (if aged 16 years or older); Lansky Performance Score of ≥60 (if less than 16 years).
  6. Adequate organ and bone marrow functions.
  7. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  8. Capable of giving signed informed consent which includes compliance with the study requirements and restrictions.

Key Exclusion Criteria:

  1. Has acute without manifestations of cGVHD.
  2. Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
  3. History or other evidence of severe illness, uncontrolled infection or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study.
  4. Known history of (HIV) or active virus (HCV) or virus (HBV).
  5. Diagnosed with another (other than malignancy for which transplant was performed) within 3 years of enrollment, unless previously treated with curative intent and must be approved by Sponsor medical monitor (for example, completely resected basal cell or squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection).
  6. Female participants who are pregnant or breastfeeding.
  7. Previous exposure to study intervention or known allergy/sensitivity to study intervention.
  8. Taking agents other than a and one calcineurin inhibitor (CNI) for treatment of cGVHD (This does not include agents being prescribed expressly for the treatment of acute GVHD).
  9. Receiving an treatment within 28 days of study entry.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Cohorts of escalating dose levels of axatilimab

    Escalating dose levels of axatilimab to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D). Intravenous (IV) infusion; axatilimab at a dose of 0.15 milligrams (mg)/kilogram (kg) to 3 mg/kg.

    Drug: axatilimab

  • Experimental
    Phase 2 Dose Expansion

    Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size. IV infusion; axatilimab at a dose of 1 mg/kg.

    Drug: axatilimab

Interventions

  • axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.

    Also known as: Niktimvo, SNDX-6352

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With DLTs

    A DLT was defined as the occurrence of any protocol-specified event within the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from Cycle 1 Day 1 to Cycle 2 Day 1) and assessed by the Investigator as not being definitely attributable to underlying disease, disease progression, inter-current illness, concomitant medications or any other alternative cause.

    Time frame: Day 1 through the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from Cycle 1 Day 1 to Cycle 2 Day 1)

  2. Phase 1: Recommended Phase 2 Dose (RP2D)

    The RP2D was determined in discussion with the Sponsor, Medical Monitor, and Dose Determination Phase Investigators and was based on observations from the Phase 1 of the study (clinical benefit in chronic graft versus host disease \[cGVHD\] and pharmacokinetic/pharmacodynamic effects).

    Time frame: Day 1 through the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from C1D1 to C2D1)

  3. Phase 2: Overall Response Rate (ORR) as Assessed by the Number of Participants With Complete Response (CR) or Partial Response (PR) at Cycle 7 Day 1 (Day 168)

    CR or PR was defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in cGVHD.CR was defined as resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. ORR was defined as the percentage of participants achieving a best overall response of CR or PR .ORR calculated as: (number of participants with best overall response as CR or PR)/total number of participants.

    Time frame: Cycle 7 Day 1 (Day 168)

Secondary outcomes

  1. Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration for SNDX-6352

    Blood samples were collected for determination of SNDX-6352 concentration.

    Time frame: Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15

  2. Phase 1: Observed Maximum Plasma Concentration for SNDX-6352

    Blood samples were collected for determination of SNDX-6352 concentration.

    Time frame: Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15

  3. Phase 1: Time to Observed Maximum Plasma Concentration

    Blood samples were collected for determination of SNDX-6352 concentration.

    Time frame: Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15

  4. Phase 1: Changes From Baseline in Colony-Stimulating Factor-1 (CSF-1) and Interleukin (IL-34) Serum Concentrations

    Blood samples were collected for determination of serum concentrations.

    Time frame: Baseline, Cycle 1 Day 8, Day 15, predose at Cycle 2 Day 1, Cycle 4 Day 1 (28-day cycles), and end of treatment (EOT) (median duration of treatment = 7 months)

  5. Phase 1: Percent Change From Baseline in Nonclassical Monocytes (CD14+CD16++)

    Blood samples were collected for determination nonclassical monocytes levels.

    Time frame: Baseline, Day 8, Day 15, predose at Cycle 2 Day 1, Cycle 4 Day 1, and EOT (median duration of treatment = 7 months)

  6. Phase 1: Number of Participants Positive for Anti-Drug Antibodies (ADA)

    Blood samples were collected for ADA assessment. A participant was considered ADA positive if at least 1 postbaseline sample was ADA positive.

    Time frame: Predose on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 3 Day 1, Day 1 of each subsequent cycle through EOT plus 30 days after last dose (safety follow-up) (median duration of treatment = 7 months)

  7. Phase 2: Best Overall Response (BOR), as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

    Physician-reported global cGVHD activity assessment and cGVHD response determination. Best overall response was calculated as percent of participants with a response of CR or PR.

    Time frame: Day 1 of each 28-Day cycle up to Cycle 7 Day 1

  8. Phase 2: Failure Free Survival (FFS)

    FFS was defined as the time from first dose of study intervention to unequivocal progression of cGVHD or relapse of underlying malignancy or addition of another systemic immune suppressive therapy or discontinuation of study treatment due to toxicity or death for any reason. Unequivocal progression of cGVHD is defined as treatment discontinuation due to clinical progression. The duration of FFS was evaluated using organ-specific cGVHD activity assessment form and and summarized descriptively using the Kaplan-Meier method.

    Time frame: From first dose of study intervention (Day 1) up to 27 months

  9. Phase 2: Duration of Response (DOR)

    DOR was defined as the time of initial response until documented progression or start of another systemic treatment as assessed by the Kaplan-Meir method.

    Time frame: Day 1 of each 28-Day cycle for up to 12 cycles

  10. Phase 2: Sustained Response Rate (SRR)

    SSR of CR or PR ≥20 weeks was defined as rate of CR or PR lasting for at least 20 weeks from the time of initial response.

    Time frame: Day 1 of each 28-Day cycle for up to 12 cycles

  11. Phase 2: Organ-specific Response Rate Based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

    The percentage of participants with a response (CR/PR) in the skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, or joints and fascia were assessed using the NIH Consensus Development Project on Clinical Trials.

    Time frame: Day 1 of each 28-Day cycle for up to 12 cycles

  12. Phase 2: Number of Participants With a Joint and Fascia Response Based on Refined NIH Response Algorithm for cGVHD

    Time frame: Day 1 of each 28-Day cycle for up to 12 cycles

  13. Phase 2: Number of Participants With A Lee Symptom Scale Summary Score Decrease of at Least 7 Points From Baseline

    The Lee cGVHD symptom questionnaire asked participants to indicate the degree of "bother" that they experienced during the past 7 days due to symptoms in 7 domains potentially affected by chronic GVHD (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) using a 5-point Likert scale from 0 "not at all" to 4 "extremely." Scores were normalized (0 to 100 scale) and the number of participants with a ≥ 7-point decrease in normalized score was calculated. A decrease in score indicated improvement in symptoms.

    Time frame: Day 1 of each 28-Day cycle for up to 12 cycles

  14. Phase 2: Number of Participants With a ≥50% Reduction in Prednisone Equivalent Dosage Lasting at Least 28 Days

    Time frame: Day 1 of each 28-Day cycle for up to 12 cycles

  15. Phase 2: Number of Participants Who Discontinued Calcineurin Inhibitor Use

    Time frame: Day 1 of each 28-Day cycle for up to 12 cycles

07

Results

Posted Nov 27, 2024

Participant flow

Participant flow — Overall Study
MilestonePhase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4WPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Started1136723
Received at least 1 dose of study treatment1136623
Dose-limiting toxicity (dlt) evaluable113660
Completed011339
Not completed1023414
Withdrew: Investigator's decision000107
Withdrew: Withdrawal by subject000002
Withdrew: Progressive disease101034
Withdrew: Difficulty coming into site000001
Withdrew: Death001000
Withdrew: Drug intolerance000100
Withdrew: Noncompliance with follow-up visit000100
Withdrew: Not treated000010

Outcome measures

PrimaryPhase 1: Number of Participants With DLTs

A DLT was defined as the occurrence of any protocol-specified event within the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from Cycle 1 Day 1 to Cycle 2 Day 1) and assessed by the Investigator as not being definitely attributable to underlying disease, disease progression, inter-current illness, concomitant medications or any other alternative cause.

Time frame:
Day 1 through the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from Cycle 1 Day 1 to Cycle 2 Day 1)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With DLTs
ParticipantsPhase 1 Dose Escalation: SNDX-6352 0.15 mg/kgPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kgPhase 1 Dose Escalation: SNDX-6352 1 mg/kgPhase 1 Dose Escalation: SNDX-6352 3 mg/kgPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W
Phase 1: Number of Participants With DLTs00020
PrimaryPhase 1: Recommended Phase 2 Dose (RP2D)

The RP2D was determined in discussion with the Sponsor, Medical Monitor, and Dose Determination Phase Investigators and was based on observations from the Phase 1 of the study (clinical benefit in chronic graft versus host disease \[cGVHD\] and pharmacokinetic/pharmacodynamic effects).

Time frame:
Day 1 through the first 28 days from the first dose of SNDX-6352 or administration of the third dose (Cycle 2 Day 1), whichever is later (from C1D1 to C2D1)
Reported as:
Number · mg/kg
Phase 1: Recommended Phase 2 Dose (RP2D)
mg/kgPhase 1 Dose Determination:SNDX-6352
Phase 1: Recommended Phase 2 Dose (RP2D)1
PrimaryPhase 2: Overall Response Rate (ORR) as Assessed by the Number of Participants With Complete Response (CR) or Partial Response (PR) at Cycle 7 Day 1 (Day 168)

CR or PR was defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in cGVHD.CR was defined as resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site. ORR was defined as the percentage of participants achieving a best overall response of CR or PR .ORR calculated as: (number of participants with best overall response as CR or PR)/total number of participants.

Time frame:
Cycle 7 Day 1 (Day 168)
Reported as:
Number · percentage of participants
Phase 2: Overall Response Rate (ORR) as Assessed by the Number of Participants With Complete Response (CR) or Partial Response (PR) at Cycle 7 Day 1 (Day 168)
percentage of participantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Overall Response Rate (ORR) as Assessed by the Number of Participants With Complete Response (CR) or Partial Response (PR) at Cycle 7 Day 1 (Day 168)39.1 (19.71 to 61.46)
SecondaryPhase 1: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration for SNDX-6352

Blood samples were collected for determination of SNDX-6352 concentration.

Time frame:
Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15
Reported as:
Mean · µg*h/mL
Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration for SNDX-6352
µg*h/mLPhase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W
Cycle 1 Day 130.7 (30.7 to 30.7)96.2 (96.2 to 96.2)1546.0 (898.0 to 2140.0)10263.3 (4660.0 to 15300.0)12256.7 (6760.0 to 20700.0)
Cycle 1 Day 1522.9 (22.9 to 22.9)98.9 (98.9 to 98.9)714.0 (121.0 to 1740.0)14,055.0 (575.0 to 26,900.0)—
SecondaryPhase 1: Observed Maximum Plasma Concentration for SNDX-6352

Blood samples were collected for determination of SNDX-6352 concentration.

Time frame:
Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15
Reported as:
Mean · µg/mL
Phase 1: Observed Maximum Plasma Concentration for SNDX-6352
µg/mLPhase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W
Cycle 1 Day 14.6 (4.6 to 4.6)13.7 (13.7 to 13.7)26.7 (19.5 to 38.7)84.0 (63.0 to 106.0)82.2 (62.2 to 104.0)
Cycle 1 Day 153.5 (3.5 to 3.5)14.2 (14.2 to 14.2)27.4 (20.1 to 41.3)91.8 (65.1 to 132.0)—
SecondaryPhase 1: Time to Observed Maximum Plasma Concentration

Blood samples were collected for determination of SNDX-6352 concentration.

Time frame:
Cycle 1: predose, at 30 min (end of infusion), and at 1 hour and 8 hours on Day 1 and Day 15
Reported as:
Median · hours
Phase 1: Time to Observed Maximum Plasma Concentration
hoursPhase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W
Cycle 1 Day 11.0 (1.0 to 1.0)1.5 (1.5 to 1.5)0.6 (0.6 to 0.6)0.9 (0.6 to 7.5)1.0 (0.5 to 7.9)
Cycle 1 Day 150.6 (0.6 to 0.6)0.5 (0.5 to 0.5)1.0 (0.6 to 1.5)1.0 (0.6 to 1.1)—
SecondaryPhase 1: Changes From Baseline in Colony-Stimulating Factor-1 (CSF-1) and Interleukin (IL-34) Serum Concentrations

Blood samples were collected for determination of serum concentrations.

Time frame:
Baseline, Cycle 1 Day 8, Day 15, predose at Cycle 2 Day 1, Cycle 4 Day 1 (28-day cycles), and end of treatment (EOT) (median duration of treatment = 7 months)
Reported as:
Median · pg/mL
Phase 1: Changes From Baseline in Colony-Stimulating Factor-1 (CSF-1) and Interleukin (IL-34) Serum Concentrations
pg/mLPhase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W
CSF-1 Cycle 1 Day 82.0 (2 to 2)602.0 (602 to 602)364480.0 (211185 to 400666)544837.5 (433627 to 613511)451482.0 (366543 to 697378)
CSF-1 Cycle 1 Day 1569.0 (69 to 69)-87.0 (-87 to -87)680.0 (-418 to 1556)897522.0 (75411 to 966627)821180.5 (581543 to 990015)
CSF-1 Cycle 2 Day 119.0 (19 to 19)227.0 (227 to 227)400.0 (-126 to 60066)1474438.5 (1439355 to 1509522)773476.0 (11 to 1029015)
CSF-1 Cycle 4 Day 1—229.0 (229 to 229)465.0 (-319 to 1378480)899337.5 (-680 to 1799355)1386196.5 (603378 to 2169015)
CSF-1 EOT63.0 (63 to 63)———1709787.0 (1709787 to 1709787)
IL-34 Cycle 1 Day 80 (0 to 0)0 (0 to 0)156.7 (86 to 409)576.2 (316 to 929)286.7 (81 to 775)
IL-34 Cycle 1 Day 150 (0 to 0)0 (0 to 0)0 (0 to 0)690.7 (199 to 1259)456.7 (216 to 744)
IL-34 Cycle 2 Day 10 (0 to 0)0 (0 to 0)0 (0 to 42)1133.7 (979 to 1289)190.7 (0 to 931)
IL-34 Cycle 4 Day 1—0 (0 to 0)0 (0 to 395)569.4 (0 to 1139)533.7 (241 to 827)
IL-34 EOT0 (0 to 0)———676.7 (676.7 to 676.7)
SecondaryPhase 1: Percent Change From Baseline in Nonclassical Monocytes (CD14+CD16++)

Blood samples were collected for determination nonclassical monocytes levels.

Time frame:
Baseline, Day 8, Day 15, predose at Cycle 2 Day 1, Cycle 4 Day 1, and EOT (median duration of treatment = 7 months)
Reported as:
Median · percent change
Phase 1: Percent Change From Baseline in Nonclassical Monocytes (CD14+CD16++)
percent changePhase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W
Cycle 1 Day 8—-41.7 (-41.7 to -41.7)-92.7 (-97 to -89)-95.7 (-98 to -90)-81.4 (-90 to -33)
Cycle 1 Day 15—-66.7 (-66.7 to -66.7)242.8 (-31 to 517)-96.5 (-98 to -94)-81.5 (-84 to 67)
Cycle 1 Day 22————-90.9 (-90.9 to -90.9)
Cycle 2 Day 1—-58.3 (-58.3 to -58.3)-31.0 (-31.0 to -31.0)-94.4 (-94.4 to -94.4)-67.5 (-81 to 167)
Cycle 4 Day 1—-16.7 (-16.7 to -16.7)273.5 (41 to 506)-76.5 (-99 to -54)-82.5 (-91 to -74)
EOT————-75.0 (-75.0 to -75.0)
SecondaryPhase 1: Number of Participants Positive for Anti-Drug Antibodies (ADA)

Blood samples were collected for ADA assessment. A participant was considered ADA positive if at least 1 postbaseline sample was ADA positive.

Time frame:
Predose on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 3 Day 1, Day 1 of each subsequent cycle through EOT plus 30 days after last dose (safety follow-up) (median duration of treatment = 7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants Positive for Anti-Drug Antibodies (ADA)
ParticipantsPhase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4W
Phase 1: Number of Participants Positive for Anti-Drug Antibodies (ADA)00132
SecondaryPhase 2: Best Overall Response (BOR), as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

Physician-reported global cGVHD activity assessment and cGVHD response determination. Best overall response was calculated as percent of participants with a response of CR or PR.

Time frame:
Day 1 of each 28-Day cycle up to Cycle 7 Day 1
Reported as:
Number · percentage of participants
Phase 2: Best Overall Response (BOR), as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
percentage of participantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Best Overall Response (BOR), as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD78.3 (56.3 to 92.54)
SecondaryPhase 2: Failure Free Survival (FFS)

FFS was defined as the time from first dose of study intervention to unequivocal progression of cGVHD or relapse of underlying malignancy or addition of another systemic immune suppressive therapy or discontinuation of study treatment due to toxicity or death for any reason. Unequivocal progression of cGVHD is defined as treatment discontinuation due to clinical progression. The duration of FFS was evaluated using organ-specific cGVHD activity assessment form and and summarized descriptively using the Kaplan-Meier method.

Time frame:
From first dose of study intervention (Day 1) up to 27 months
Reported as:
Median · months
Phase 2: Failure Free Survival (FFS)
monthsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Failure Free Survival (FFS)16.9 (9.3 to NA)
SecondaryPhase 2: Duration of Response (DOR)

DOR was defined as the time of initial response until documented progression or start of another systemic treatment as assessed by the Kaplan-Meir method.

Time frame:
Day 1 of each 28-Day cycle for up to 12 cycles
Reported as:
Median · months
Phase 2: Duration of Response (DOR)
monthsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Duration of Response (DOR)9.53 (1.87 to 17.05)
SecondaryPhase 2: Sustained Response Rate (SRR)

SSR of CR or PR ≥20 weeks was defined as rate of CR or PR lasting for at least 20 weeks from the time of initial response.

Time frame:
Day 1 of each 28-Day cycle for up to 12 cycles
Reported as:
Number · percentage of participants
Phase 2: Sustained Response Rate (SRR)
percentage of participantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Sustained Response Rate (SRR)39.1 (19.7 to 61.5)
SecondaryPhase 2: Organ-specific Response Rate Based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

The percentage of participants with a response (CR/PR) in the skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, or joints and fascia were assessed using the NIH Consensus Development Project on Clinical Trials.

Time frame:
Day 1 of each 28-Day cycle for up to 12 cycles
Reported as:
Number · percentage of participants
Phase 2: Organ-specific Response Rate Based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
percentage of participantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Esophagus83.3 (35.88 to 99.58)
Eyes18.8 (4.05 to 45.65)
Joints and Fascia76.5 (50.1 to 93.19)
Liver0 (0 to 70.76)
Lower GI100.0 (39.76 to 100)
Lungs33.3 (7.49 to 70.07)
Mouth75.0 (42.81 to 94.51)
Skin19.0 (5.45 to 41.91)
Upper GI100.0 (39.76 to 100)
Global47.8 (26.82 to 69.41)
SecondaryPhase 2: Number of Participants With a Joint and Fascia Response Based on Refined NIH Response Algorithm for cGVHD
Time frame:
Day 1 of each 28-Day cycle for up to 12 cycles
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With a Joint and Fascia Response Based on Refined NIH Response Algorithm for cGVHD
ParticipantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Improved10
Stable7
SecondaryPhase 2: Number of Participants With A Lee Symptom Scale Summary Score Decrease of at Least 7 Points From Baseline

The Lee cGVHD symptom questionnaire asked participants to indicate the degree of "bother" that they experienced during the past 7 days due to symptoms in 7 domains potentially affected by chronic GVHD (skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, emotional distress) using a 5-point Likert scale from 0 "not at all" to 4 "extremely." Scores were normalized (0 to 100 scale) and the number of participants with a ≥ 7-point decrease in normalized score was calculated. A decrease in score indicated improvement in symptoms.

Time frame:
Day 1 of each 28-Day cycle for up to 12 cycles
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With A Lee Symptom Scale Summary Score Decrease of at Least 7 Points From Baseline
ParticipantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Number of Participants With A Lee Symptom Scale Summary Score Decrease of at Least 7 Points From Baseline12
SecondaryPhase 2: Number of Participants With a ≥50% Reduction in Prednisone Equivalent Dosage Lasting at Least 28 Days
Time frame:
Day 1 of each 28-Day cycle for up to 12 cycles
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With a ≥50% Reduction in Prednisone Equivalent Dosage Lasting at Least 28 Days
ParticipantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Number of Participants With a ≥50% Reduction in Prednisone Equivalent Dosage Lasting at Least 28 Days5
SecondaryPhase 2: Number of Participants Who Discontinued Calcineurin Inhibitor Use
Time frame:
Day 1 of each 28-Day cycle for up to 12 cycles
Reported as:
Count of participants · Participants
Phase 2: Number of Participants Who Discontinued Calcineurin Inhibitor Use
ParticipantsPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2W
Phase 2: Number of Participants Who Discontinued Calcineurin Inhibitor Use0

Adverse events

Collected over From first dose of study drug up to EOT plus 90 days after last dose (safety follow-up) (median duration of treatment = 7 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SNDX-6352 0.15 mg/kg Q2W0/1 (0%)1/1 (100%)1/1 (100%)
SNDX-6352 0.5 mg/kg Q2W0/1 (0%)1/1 (100%)1/1 (100%)
SNDX-6352 1 mg/kg Q2W1/26 (3.8%)12/26 (46.2%)26/26 (100%)
SNDX-6352 3 mg/kg Q2W0/6 (0%)3/6 (50%)6/6 (100%)
SNDX-6352 3 mg/kg Q4W0/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventSNDX-6352 0.15 mg/kg Q2WSNDX-6352 0.5 mg/kg Q2WSNDX-6352 1 mg/kg Q2WSNDX-6352 3 mg/kg Q2WSNDX-6352 3 mg/kg Q4W
PneumoniaInfections and infestations0/11/13/260/60/6
HepatitisHepatobiliary disorders1/10/10/260/60/6
Spinal fractureInjury, poisoning and procedural complications0/11/10/260/60/6
CellulitisInfections and infestations0/10/10/261/61/6
PyrexiaGeneral disorders0/10/11/261/60/6
Abdominal painGastrointestinal disorders0/10/10/260/61/6
Acute kidney injuryRenal and urinary disorders0/10/10/261/60/6
BronchiectasisRespiratory, thoracic and mediastinal disorders0/10/10/260/61/6
BronchitisInfections and infestations0/10/10/260/61/6
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/10/10/260/61/6
Most frequent other events
Showing 10 of 178
Most frequent other events
EventSNDX-6352 0.15 mg/kg Q2WSNDX-6352 0.5 mg/kg Q2WSNDX-6352 1 mg/kg Q2WSNDX-6352 3 mg/kg Q2WSNDX-6352 3 mg/kg Q4W
FatigueGeneral disorders0/11/112/263/62/6
Oedema peripheralGeneral disorders1/10/14/261/62/6
MalaiseGeneral disorders1/10/11/262/60/6
Aspartate aminotransferase increasedInvestigations1/10/16/264/64/6
Blood creatine phosphokinase increasedInvestigations0/10/13/266/65/6
Alanine aminotransferase increasedInvestigations1/10/15/264/63/6
Blood lactate dehydrogenase increasedInvestigations0/11/14/264/63/6
Amylase increasedInvestigations1/10/16/264/60/6
Gamma-glutamyltransferase increasedInvestigations1/10/12/261/61/6
Blood alkaline phosphatase increasedInvestigations1/10/12/261/60/6

Baseline characteristics

Safety Analysis Set: All participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4WPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2WTotal
Mean64.0 (64 to 64)48.0 (48 to 48)43.7 (29 to 66)61.0 (53 to 73)59.2 (31 to 73)52.5 (16 to 69)54.7 (16 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4WPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2WTotal
Female00132915
Male112341425
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4WPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2WTotal
Hispanic or Latino0000000
Not Hispanic or Latino113662239
Unknown or Not Reported0000011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1 Dose Escalation: SNDX-6352 0.15 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 0.5 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 1 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q2WPhase 1 Dose Escalation: SNDX-6352 3 mg/kg Q4WPhase 2 Dose Expansion: SNDX-6352 1 mg/kg Q2WTotal
Race — Black or African American1001125
Race — White013552034
Race — Other0000011
08

Study locations

11 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • City of Hope
    Duarte, California 91010, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Indiana University Health Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University of Minnesota Medical Center
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37212-3505, United States
  • University of Utah Health Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Yang YO, Sokolov V, Volkova A, Liu X, Leon C, Kosinsky Y, Barker B, Zhang X, Ordentlich P, Sheng J, Chen X. Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease. Clin Pharmacol Ther. 2025 Mar;117(3):704-715. doi: 10.1002/cpt.3503. Epub 2024 Dec 20. PubMed 39704205 ↗
  • Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2023 Apr 1;41(10):1864-1875. doi: 10.1200/JCO.22.00958. Epub 2022 Dec 2. PubMed 36459673 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Aug 2022, 45 months.

Results were first posted in Nov 2024, 2 years 3 months after primary completion. A results delay was requested in Aug 2023.

Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Jul 27, 2018
StartActual
Nov 1, 2018
Primary completionActual
Aug 12, 2022
CompletionActual
Oct 18, 2024
Results delay requested
Aug 1, 2023
Results first posted
Nov 27, 2024
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03604692
Responsible party
Sponsor
First posted
Jul 27, 2018
Start date
Nov 1, 2018
Primary completion
Aug 12, 2022
Completion
Oct 18, 2024
Results posted
Nov 27, 2024
Last update
Sep 15, 2025

Study contacts

Vedran Radojcic, M.D.
study director · Syndax Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion